Stocks · News reference
Contineum Therapeutics has updated its ongoing Phase 2 clinical trial for idiopathic pulmonary fibrosis by adding an imaging-based assessment criterion.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analysts have updated the 12-month price target for Contineum Therapeutics, Inc. to $21.43, reflecting a potential upside of approximately 121% based on the November 3, 2026, closing price.
Contineum Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2026.
Filed: 2026-11-03 AccNo: 0001628280-26-069493 Size: 254 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Contineum Therapeutics, Inc. announced that its management team is scheduled to participate in a fireside chat at the Stifel 2026 Healthcare Conference on November 12, 2026.
Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR received a new $60 target.